

CD82 (ST6) Antibody (C-term)

Purified Rabbit Polyclonal Antibody (Pab) Catalog # AP6250a

Specification

CD82 (ST6) Antibody (C-term) - Product Information

Application WB, IHC-P, FC,E **Primary Accession** P27701 Other Accession NP 002222 Human, Mouse Reactivity Host **Rabbit** Clonality **Polyclonal** Isotype Rabbit IgG **Antigen Region** 239-267

CD82 (ST6) Antibody (C-term) - Additional Information

Gene ID 3732

Other Names

CD82 antigen, C33 antigen, IA4, Inducible membrane protein R2, Metastasis suppressor Kangai-1, Suppressor of tumorigenicity 6 protein, Tetraspanin-27, Tspan-27, CD82, CD82, KAI1, SAR2, ST6, TSPAN27

Target/Specificity

This CD82 (ST6) antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 239-267 amino acids from the C-terminal region of human CD82 (ST6).

Dilution

WB~~1:1000 IHC-P~~1:10~50 FC~~1:10~50

Format

Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.

Storage

Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.

Precautions

CD82 (ST6) Antibody (C-term) is for research use only and not for use in diagnostic or therapeutic procedures.

CD82 (ST6) Antibody (C-term) - Protein Information

Name CD82





Synonyms KAI1, SAR2, ST6, TSPAN27

Function Associates with CD4 or CD8 and delivers costimulatory signals for the TCR/CD3 pathway.

Cellular Location

Cell membrane; Multi-pass membrane protein


Tissue Location Lymphoid specific.

CD82 (ST6) Antibody (C-term) - Protocols

Provided below are standard protocols that you may find useful for product applications.


- Western Blot
- Blocking Peptides
- Dot Blot
- <u>Immunohistochemistry</u>
- Immunofluorescence
- Immunoprecipitation
- Flow Cytomety
- Cell Culture

CD82 (ST6) Antibody (C-term) - Images




All lanes : Anti-ST6 Antibody (C253) at 1:1000 dilution Lane 1: Jurkat whole cell lysate Lane 2: Raji whole cell lysate Lysates/proteins at 20 μ g per lane. Secondary Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated at 1/10000 dilution. Predicted band size : 30 kDa Blocking/Dilution buffer: 5% NFDM/TBST.






Anti-ST6 Antibody (C253) at 1:1000 dilution + Jurkat whole cell lysate Lysates/proteins at 20 μ g per lane. Secondary Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated at 1/10000 dilution. Predicted band size : 30 kDa Blocking/Dilution buffer: 5% NFDM/TBST.




Western blot analysis of ST6 (arrow) using ST6 Antibody (C-term) (Cat.#AP6250a). 293 cell lysates (2 ug/lane) either nontransfected (Lane 1) or transiently transfected with the CD82 gene (Lane 2) (Origene Technologies).





Formalin-fixed and paraffin-embedded human lymph with CD82 (ST6) Antibody (C-term), which was peroxidase-conjugated to the secondary antibody, followed by DAB staining. This data demonstrates the use of this antibody for immunohistochemistry; clinical relevance has not been evaluated.



Flow cytometric analysis of HepG2 cells using CD82 (ST6) Antibody (C-term)(bottom histogram) compared to a negative control cell (top histogram). FITC-conjugated goat-anti-rabbit secondary antibodies were used for the analysis.

CD82 (ST6) Antibody (C-term) - Background

The ST6 metastasis suppressor gene product is a membrane glycoprotein that is a member of the transmembrane 4 superfamily. Expression has been shown to be downregulated in tumor progression of human cancers and can be activated by p53 through a consensus binding sequence in the promoter. Its expression and that of p53 are strongly correlated, and the loss of expression of these two proteins is associated with poor survival for prostate cancer patients.

CD82 (ST6) Antibody (C-term) - References

Zhang, X.A., et al., J. Biol. Chem. 278(29):27319-27328 (2003). Zhang, X.A., et al., Cancer Res. 63(10):2665-2674 (2003). Yang, J., et al., Ai Zheng 22(5):533-536 (2003).





Sauer, G., et al., Oncol. Rep. 10(2):405-410 (2003). Ito, Y., et al., Pathol Res Pract 199(2):79-83 (2003).